PubRank

Bret Lashner

Author PubWeight™ 22.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2010 2.74
2 Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006 2.73
3 Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2007 2.55
4 Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008 2.29
5 Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006 1.87
6 Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol 2005 1.10
7 Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012 1.08
8 Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010 1.04
9 Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005 0.93
10 Hospital readmissions in patients with inflammatory bowel disease. Am J Gastroenterol 2013 0.91
11 Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract 2008 0.90
12 Retracted Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 2011 0.88
13 Risk factors for clinical phenotypes of Crohn's disease of the ileal pouch. Am J Gastroenterol 2006 0.87
14 Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004 0.81
15 Diagnosis and treatment of ileal pouch diseases in patients with underlying ulcerative colitis. Curr Treat Options Gastroenterol 2006 0.79
16 Can we immunogenotypically and immunophenotypically profile patients who are at risk for pouchitis? Am J Gastroenterol 2004 0.78
17 Random versus targeted biopsies for colorectal cancer surveillance in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2010 0.77
18 Chemoprevention of colorectal cancer: slow, steady progress. Cleve Clin J Med 2003 0.75
19 Continuing Medical Education Questions: October 2015. Am J Gastroenterol 2015 0.75
20 Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. J Clin Gastroenterol 2016 0.75
21 Our Vision for the Future of Inflammatory Bowel Diseases: Research, Innovations, and Controversies. Inflamm Bowel Dis 2017 0.75
22 Quality commitment: the newly established American College of Gastroenterology Quality Council to meet the needs of clinical gastroenterology. Am J Gastroenterol 2013 0.75
23 Continuing Medical Education Questions: October 2015. Am J Gastroenterol 2015 0.75
24 A case of refractory diarrhea. Cleve Clin J Med 2008 0.75